Eli Lilly (NYSE:LLY) drew attention as GLP-1 demand led healthcare and large-cap pharma momentum steadied.

Eli Lilly has guided fiscal 2026 revenue to between $85 billion and $87 billion, putting the $100 billion annual revenue milestone within reach. The…

On August 13, 2026, Novo Nordisk A/S (NYSE:NVO) CEO Mike Doustdar told Reuters that investors are underestimating how much the obesity drug market will fragment as new treatments arrive. He pushed back on the idea that Novo and Eli Lilly and Company (NYSE:LLY) are locked in a zero-sum battle for the same shrinking pool of […]

Eli Lilly (LLY) has moved further into obesity and diabetes care with the UK launch of its once daily oral GLP-1 pill Foundayo, orforglipron, shortly after lifting its full year outlook. See our latest analysis for Eli Lilly. The launch of Foundayo comes during a strong run for Eli Lilly’s stock, with a 90 day share price return of 17.91% and a 1 year total shareholder return of 81.69%. This indicates momentum that has built rather than faded over multiple years. If you are interested in how...

The U.S. Food and Drug Administration (FDA) has cleared Roche and partner Eli Lilly’s blood test to help identify signs of Alzheimer’s disease in people aged 55 and older with cognitive decline.

/PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P)...

South Korea biotech Rznomics joins Lilly Gateway Labs in San Diego to accelerate RNA-editing therapeutics research. Discover the partnership details.

On August 13, 2026, Novo Nordisk A/S (NYSE:NVO) CEO Mike Doustdar told Reuters that investors are underestimating how much the obesity drug market will fragment as new treatments arrive. He pushed back on the idea that Novo and Eli Lilly and Company (NYSE:LLY) are locked in a zero-sum battle for the same shrinking pool of […]

On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide. It is an experimental obesity drug still in Phase 3 trials and not yet approved by regulators anywhere. Why This Matters Lilly is trying to shut down a […]

South Korea's RNA gene therapy developer Rznomics announced it is joining Eli Lilly and Company's Lilly Gateway Labs innovation hub in San Diego,…

**media[1187248]**SEONGNAM, South Korea, Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innovation hub designed to empower biotechnology companies to advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives. Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.

Eli Lilly just delivered one of the most staggering quarters in Big Pharma history, yet Wall Street is barely reacting. Three catalysts in the next 18 months could either push shares to levels few analysts dare to print or expose the cracks in a very expensive story.

Eli Lilly's $67 Billion Surge Brings Shares Close to Wall Street's Consensus Target - TechStock²